Scarica l'app Stockscreener
7.61
4.10%
0.30
Dopo l'orario di chiusura:
7.63
0.02
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Precedente Chiudi:
$7.31
Aprire:
$7.19
Volume 24 ore:
975.66K
Relative Volume:
0.70
Capitalizzazione di mercato:
$1.20B
Reddito:
$61.10M
Utile/perdita netta:
$-138.36M
Rapporto P/E:
-5.637
EPS:
-1.35
Flusso di cassa netto:
$-90.59M
1 W Prestazione:
+0.53%
1M Prestazione:
+1.33%
6M Prestazione:
-33.07%
1 anno Prestazione:
+45.79%
Intervallo 1D:
$7.12
$7.80
Intervallo di 1 settimana:
$6.935
$7.825
Portata 52W:
$4.06
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Nome
Ocular Therapeutix Inc
Settore
Industria
Telefono
781-357-4000
Indirizzo
15 CROSBY DRIVE, BEDFORD, MA
Confronta OCUL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
7.61 | 1.20B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | William Blair | Outperform |
| 2025-03-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-11 | Iniziato | Needham | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-20 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-05-31 | Ripresa | Piper Sandler | Overweight |
| 2024-02-09 | Iniziato | BofA Securities | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-08-10 | Ripresa | Berenberg | Buy |
| 2021-08-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-11-13 | Reiterato | Raymond James | Strong Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Downgrade | Cowen | Outperform → Market Perform |
| 2019-05-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Iniziato | Raymond James | Strong Buy |
| 2018-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2017-10-24 | Iniziato | Guggenheim | Buy |
| 2017-07-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-07-12 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-08-11 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
How To Trade (OCUL) - news.stocktradersdaily.com
Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24% - simplywall.st
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM - openPR.com
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listin - GuruFocus
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Hire: Ocular Therapeutix Strengthens Leadership with Key Payer Access Executive - Stock Titan
Key Trends Shaping the Future of Ocular Implants Market:Ocular Therapeutix Launches Clinical Trial For Axit... - WhaTech
William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - MSN
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Hypertension Pipeline Analysis and Clinical Trials - openPR.com
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts - Benzinga
William Blair starts Ocular Therapeutix stock with Outperform By Investing.com - Investing.com Canada
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
William Blair Initiates Ocular Therapeutix With Outperform Rating - marketscreener.com
Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment - TipRanks
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care - Investing.com India
How to Take Advantage of moves in (OCUL) - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Ocular Therapeutix™ to Participate in Two Investor Conferences in April - The Manila Times
Exclusive: Ocular Therapeutix Leadership Sets Major Investor Presentations for April - Stock Titan
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - simplywall.st
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
What 4 Analyst Ratings Have To Say About Ocular Therapeutix - Benzinga
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - Nasdaq
Ocular's Axpaxli May Take Wet AMD Market Share, RBC Says -March 18, 2025 at 11:38 am EDT - Marketscreener.com
RBC Initiates Ocular Therapeutix at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
Ocular rises as Needham issues new Buy on lead candidate - MSN
When (OCUL) Moves Investors should Listen - news.stocktradersdaily.com
Ocular Therapeutix (OCUL) Stock Movement Driven by Analyst Cover - GuruFocus
Why Ocular Therapeutix Was Bumping Higher This Week - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by Analysts at Needham & Company LLC - Defense World
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - AOL.com
Needham Initiates Ocular Therapeutix at Buy With $15 Price Target - MarketScreener
This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Needham Initiates Coverage of Ocular Therapeutix (OCUL) with Buy Recommendation - Nasdaq
Ocular Therapeutix initiated with a Buy at Needham - TipRanks
Ocular Therapeutix at Leerink Conference: Strategic Insights on XPAXLI By Investing.com - Investing.com Canada
Ocular Therapeutix at Leerink Conference: Strategic Insights on AXPAXLI By Investing.com - Investing.com Australia
Ocular Therapeutix Awards Stock Options and RSUs to New Employee - StockTitan
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Pessimistic Outlook of OCUL Q1 Earnings - Defense World
Ocular Therapeutix: Axpaxli’s Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright - Defense World
Ocular Therapeutix, Inc. to Host Earnings Call - ACCESS Newswire
Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - MSN
Ocular Therapeutix Inc Azioni (OCUL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):